Floatz logo

Vobramitamab Duocarmazine

Advanced Solid Tumor, Adult

MacroGenicsPhase 1/2Dormant
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Advanced Solid Tumor, Adult cohort.

Asset / SponsorPhaseRating
Camonsertib
Repare Therapeutics
Phase 1/2CC
cgt4255
Cogent Biosciences, Inc.
Phase 1CC

Same molecule, other indications

Vobramitamab Duocarmazine is also rated in:

castration-resistant prostate carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
melanomaDormant
CC
Indicative ·
44 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →